Beranda › PPOK › Oklahoma › Oklahoma City
Uji klinis PPOK di Oklahoma City, OK
5 studi untuk PPOK mencari peserta di lokasi sekitar Oklahoma City (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Menerima pesertaFase 3
- Research Site, Oklahoma City
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Menerima pesertaFase 2
- Research Site, Oklahoma City
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Menerima pesertaFase 3
- Research Site, Oklahoma City
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Menerima pesertaFase 3
- Research Site, Oklahoma City
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Menerima pesertaStudi observasional
- Hightower Clinical, Oklahoma City
Uji klinis PPOK di kota lain
- Philadelphia, PA23 studi
- Miami, FL18 studi
- Birmingham, AL17 studi
- Boston, MA17 studi
- Houston, TX15 studi
- Orlando, FL15 studi
- Baltimore, MD14 studi
- Chicago, IL14 studi
- Dallas, TX12 studi
- Pittsburgh, PA12 studi
- New York City, NY11 studi
- Ann Arbor, MI10 studi
Studi lain di Oklahoma City
- Kanker Paru Non-Sel Kecil28 studi
- Kanker Ovarium28 studi
- Kanker Endometrium25 studi
- Kanker Kolorektal22 studi
- Kanker Prostat21 studi
- Kanker Paru19 studi
- Kanker Payudara17 studi
- Kanker Metastatik15 studi
- Kanker (semua jenis)14 studi
- Leukemia Mieloid Akut14 studi
- Karsinoma Sel Skuamosa Kepala dan Leher13 studi
- Kanker Pankreas11 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.